2018
DOI: 10.1016/j.cancergen.2018.05.002
|View full text |Cite
|
Sign up to set email alerts
|

Corrigendum to “Potential circulating miRNA signature for early detection of NSCLC” [Cancer Genetics 216–217 (2017) 150–158]

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

0
3
0

Year Published

2018
2018
2021
2021

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(3 citation statements)
references
References 0 publications
0
3
0
Order By: Relevance
“…Hence, circulating miRNAs may potentially serve as useful biomarkers to screen and manage NSCLC patients (5,6,10,11). Indeed, in a recent study on lung cancer, a plasma-based microRNA signature classifier (MSC) was used to screen high-risk NSCLC individuals, and improved the specificity and reduced the false-positive rate of low-dose computed tomography (LDCT) (12)(13)(14). In other reports, plasma miRNAs such as miR-21-5p, miR-141-3p, miR-145-5p, miR-155-5p, and miR-223-3p were found to be up-regulated in tumor node metastasis (TNM) stages I and II of NSCLC patients (13,15).…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…Hence, circulating miRNAs may potentially serve as useful biomarkers to screen and manage NSCLC patients (5,6,10,11). Indeed, in a recent study on lung cancer, a plasma-based microRNA signature classifier (MSC) was used to screen high-risk NSCLC individuals, and improved the specificity and reduced the false-positive rate of low-dose computed tomography (LDCT) (12)(13)(14). In other reports, plasma miRNAs such as miR-21-5p, miR-141-3p, miR-145-5p, miR-155-5p, and miR-223-3p were found to be up-regulated in tumor node metastasis (TNM) stages I and II of NSCLC patients (13,15).…”
Section: Introductionmentioning
confidence: 99%
“…Indeed, in a recent study on lung cancer, a plasma-based microRNA signature classifier (MSC) was used to screen high-risk NSCLC individuals, and improved the specificity and reduced the false-positive rate of low-dose computed tomography (LDCT) (12)(13)(14). In other reports, plasma miRNAs such as miR-21-5p, miR-141-3p, miR-145-5p, miR-155-5p, and miR-223-3p were found to be up-regulated in tumor node metastasis (TNM) stages I and II of NSCLC patients (13,15). Similarly, it was reported that up-regulated serum levels of miR-210 were associated with progression-free survival (PFS), while reducing the overall survival (OS) and diseasefree survival (DFS) of NSCLC patients (16).…”
Section: Introductionmentioning
confidence: 99%
“…miRNAs represent a distinct group of non-coding RNA molecules and regulate gene expression. 7 A growing amount of evidence has shown that miRNA dysregulation is related to many human diseases and the proliferation and metastasis of various tumors, including HCC, 8 , 9 breast cancer, 10 , 11 lung cancer, 12 , 13 colorectal cancer, 14 , 15 and gastric cancer. 16 , 17 Many miRNAs in HCC show deranged profiles, for example, microRNA 135a (miRNA/miR), miR-33a, miR-122, miR-18a, and miR-31.…”
Section: Introductionmentioning
confidence: 99%